Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yet Amarin management lets him continue his drivel.....SMH
Baker Brothers still hold 26.5 mm shares. They sold 1.5 mm though
Bakers are not the only bagholders here....LOL
see: https://whalewisdom.com/stock/amrn
What is significance of May 26th?
I think Supreme Court's decision on whether to take case or not which should happen in June carries the biggest significance to getting things rolling.....
Clock is ticking this year is almost half gone so can wipe another year off the life of Vascepa in the USA for CV indication.....
No need to wait after the Supreme Court decides.
Don't see why it would take till the end of the year once the Supreme Court decides to take our case or not....
why keep waiting.....
Baker Brothers.....curious to see their holdings when they report ...
Great post.
https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired
See this re: their refusal to defend the stock price......
speaks volumes about what is going on right now.
I seriously doubt we see $30 unless SC grants cert. Management / JT fumbled any notion of us seeing $30 on that Nevada trial.
We are at $4.37.....a BP is not paying $30 for us unless SC grants cert.
JT's "it works" and continued silence has not helped one bit.
JMO
Where do you see that stated?
can you provide the link or paste below.....
Thanks
I don't think that is far-fetched at all.
Current CEO of Merck steps down June 30th.
Also we should know if SC will accept AMRN's case by end of June.
I don't see management selling AMRN until hearing back from SC....so things could line up shortly.....
During the interim KM is essentially lining things up for the BO....
Moreover, if capital gains do increase next year....more motivation for management to get a deal done so it closes this year.....
We are approaching middle of the year so clock will be ticking fast soon.
maybe he got greedy and actually thought Amarin would be $100 per share LMAO.
for sure he got duped by his general counsel though. Kennedy should have been fired immediately for filing that case in Nevada. A first year law student could have advised to avoid the 9th circuit. That decision cost Thero and others millions.
The Ninth Circuit for crying out loud. Inexcusable.
Horrible management. The kind Buffett warned about.
Yea I remember those JL proclamations along with fast nickels beats slow dimes and that Vascepa would sell itself.
Goes to show always take some profits off the table. Better to be safe than greedy. I'm glad I sold a lot in the 20s....wish I would have sold it all now.
JL appears to be long gone.
btw: I watched Buffett at the Berkshire Annual Meeting this weekend. He talked about the biggest risk to a business which is bad management. Hmmmmmm
Great now all we need is a new management team to convey any positive news to the market.
It works aināt gonna cut it. Smh.
I believe Amarin is waiting to hear back from Supreme Court if they will take their case or not. In Amarinās brief they cite this is their only product that may not reach the masses if decision is not overturned. This is a little less compelling if owned by a BP. So we should know abouf SC by end of June.
Companies do not talk BO. Yoi will find out only when it happens. Unless a company goes hostile to acquire.
If you think we are upset with our CEO, check out the Merck boards...they are livid with their CEO and the fact their stock price has declined.
Their new CEO starts July 1
Correct. There was talk that JT's big stick would yield but that has not been the case thus far.
Absent an activist or a BO.....the stock price will continue to meander until there is a noticeable increase in scripts or some action from the judicial system to change our current fate.
It's unfortunate because we all know Vascepa is a great drug but management has not been able to get out of its own way to alter the ship so to speak.
Joe Edelman, who runs Perceptive Advisors, is known for saying invest when the perception is worse than the reality because you can make a lot of money. The problem for us as you pointed out is with our current management our perception and reality are bad right now.
Merck's new CEO said they are open to all form of M&A deals.....hmmmm
Does he know about AMRN......
see link below:
https://www.fiercepharma.com/pharma/merck-says-m-a-isn-t-off-table-as-q1-sales-take-pandemic-hit
Could Merck use a lift from AMRN.......
Merck & Co. posted a slightly lower first-quarter profit and nearly flat sales as the Covid-19 pandemic and competitive pressures weighed on its revenue.
The Kenilworth, N.J.-based pharmaceutical company logged earnings of $3.19 billion, down from $3.22 billion a year earlier. Sales edged higher to $12.08 billion from $12.06 billion but fell short of analysts expectations.
Merck estimated that the Covid-19 pandemic hurt its pharmaceutical revenue by $600 million. The segmentās revenue was $10.68 billion, roughly in line with its result in last yearās first quarter. In addition to the pandemicās negative impact, Merck said its revenue was also hurt by the loss of market exclusivity for some products.
Sales of Merckās Keytruda cancer drug grew 19% year over year, but revenue from its Gardasil and Pneumovax vaccines declined by 16% and 33%, respectively.
Animal-health sales grew by 17% to $1.42 billion, a reflection of higher global demand for parasiticides and animal vaccines.
Agree. And the fact that they are taking 8 months to find his replacement tells you everything you need to know......
I find it curious that it will take 8 months to find his replacement given all the litigation Amarin is involved with.
Me thinks he will "really" be replaced with the acquiring BP's legal counsel.
Yea yea we get it end of 2021.....wink wink to be replaced by BP's counsel.
It is good news. Confirms the generics have limited supply.
Amarin has a legitimate business case to build supply: the CVD market which is still under patent.
It's not Amarin's fault the generics cannot find / build supply.
Generics are not entitled to the CVD market just because they want it. Can't cut through the back door without supply. LOL
Well the new CEO of Merck takes over July 1 when Ken Frazer, the current CEO of Merck, retires effective June 30th.
One can only dream that the new CEO kicks off his tenure with acquiring AMRN in July or August...
:)
Larrybirdlegend....are you still holding here? You have been eerily quiet as of late....what do you make of JT's announcement?
Management has failed to convince Wall Street of that. I agree generics have not taken much share but what we think is not the issue. We are at $5 bucks post European approval. We were at $6.50 when the CEO announced his retirement with just a PR.
They have succeeded in ruining all momentum / stock price. Job well done.
Elon Musk JT is not. Lol.
We are more than 2 yeard post reduce-it. Very few know about Vascepa.
Wall Street has little faith in this management team. Hence our stock is at $5 bucks. Can you blame Wall Streer? This is the same management team that rolled the dice on a trial in the 9th Circuit. A first year law student could tell you to stay away from the 9th Circuit.
Good luck with this management team. Silence appears to be golden. What a disgrace.
"it works" LOL.
SMH. Such a sad state of current affairs. Stock is in the $5s with European approval.
Strong indictment of management.
Hopefully the increase in cap gains taxes will light a fire under them. We can only hope.
Itās actually the contrary. The further out the trial the better for Amarin. Generics will have to stay close to the Marine indication for prescriptions otherwise it is more evidence that can be used. So it is an additional three years. More delays the better for Amarin.
Amarin needs to grow its scripts which is a different issue. The majority of folks dont know about Vascepa. We had an accoutant for a CEO.
What's your best guess if this low nicotine mandate actually gets issued by the FDA? I've been following this company since 2018 and I know there was discussion back then but it never came to pass. I met the old CEO at an LD Micro Conference. The story then seemed very promising but the FDA dragged its feet. I guess the Big Tobacco lobby is still powerful.
Do you truly think this time will be different? How long will they give Big Tobacco to comply?
I wonder if smokers will actually "like" the VLN cigarette. I don't smoke so I have no idea if smokers will actually like smoking it.
Thanks. Given that the new CEO's options will be priced based on market price of Amarin's stock on May 1st, I doubt he will say anything to drive up the stock price before then. LOL
Equity Participation
9.1
Subject to the terms and conditions set forth in Amarin Corporation plcās 2020 Stock Incentive Plan (the āPlanā) and the applicable equity award agreements, including, without limitation, with respect to vesting, the Executive will be entitled to:
(a)
290,200 options to purchase shares of Amarin Corporation plc, which will have an exercise price equal to the closing market price on May 1, 2021, which options will be subject to the Executiveās appointment as President and CEO of Amarin Corporation plc and subject to time-based vesting commencing on the date of this Agreement (the āVesting Start Dateā) as follows: twenty-five percent (25%) of such options shall vest on the one-year anniversary of the Vesting Start Date and the remainder shall vest in equal installments over the next 12 calendar quarters, and subject to 100% acceleration upon a Change of Control (as defined in the Plan) transaction.
7
(b)
215,200 restricted stock units subject to time-based vesting (RSUs), which RSUs will be subject to the Executiveās appointment as President and CEO of Amarin Corporation plc and otherwise subject to time-based vesting over a three-year period commencing on the date of this Agreement, and subject to 100% acceleration upon a Change of Control (as defined in the Plan) transaction.
(c)
200,000 restricted stock units subject to performance milestones (PSUs), which PSUs will be subject to the Executiveās appointment as President and CEO of Amarin Corporation plc and otherwise subject to the same performance and time-based criteria approved by the Remuneration Committee of the Board with respect to the PSU awards approved in December 2020 (but in this case the performance milestones will be the global sales and operations targets specified therein and the time-based criteria will commence as of the date of this Agreement), and subject to 100% acceleration upon a Change of Control (as defined in the Plan) transaction.
Thank you
Can you post the info for the new CEO's speech next week? When his he speaking....
Thanks
Why is that?
Larrybirdlegend---what's your latest read on things? Quite a turn of events over the last 24 hours with JT's upcoming "retirement."
Curious to hear what you think....
Good to hear from you. I imagine a BO will not happen until we hear back from the Supreme Court if they will take our case right?
I cannot see JT going forward with a BO before seeing what the SC has to say. But that's an additional two months...looks like we are talking end of June before Supreme Court decides.
Also see. UHC
Here's ruling that folks are referencing. UHC, perhaps in response to AMRN legal wranglings will not cover for TG>500 but will cover ā„150 for CARDIOVASCULAR RISK REDUCTION (PA). Big NO to generics here as they are not labeled for this indicationš $AMRNhttps://t.co/4kE8DEgETX
— TerraPharma (@TerraPharma1) March 8, 2021
Yes. See stephen rosenman discussion on stocktwits
https://stocktwits.com/stephenrosenman/message/300717671
Larrybirdlegend--where is JT's big stick? So far post EMA news....we have a nothingburger.
What gives....